Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.2K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.2K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

627
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
627
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.5K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.5K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

1.2K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.2K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.5K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.5K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

847
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
847

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common genetic determinants of vitamin D insufficiency: a genome-wide association study.

Lancet (London, England)·2010
Same author

Heart failure and incident late-life depression.

Journal of the American Geriatrics Society·2010
Same author

Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study.

The Journal of clinical endocrinology and metabolism·2010
Same author

Predicting survival and morbidity-free survival to very old age.

Age (Dordrecht, Netherlands)·2010
Same author

Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the prevalence, incidence or progression of osteoarthritis independent of body mass index.

Annals of the rheumatic diseases·2010
Same author

Paroxysmal disorders in infancy and their risk factors in a population-based cohort: the Generation R Study.

Developmental medicine and child neurology·2010

Related Experiment Video

Updated: Mar 24, 2026

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.5K

Proton pump inhibitors and gastroenteritis.

Robert-Jan Hassing1,2, Annelies Verbon3, Herman de Visser4

  • 1Department of Epidemiology, Erasmus Medical Centre, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.

European Journal of Epidemiology
|March 11, 2016
PubMed
Summary

Proton pump inhibitor (PPI) use is linked to a higher risk of bacterial gastroenteritis. This study found current PPI therapy associated with increased bacterial gastroenteritis risk.

Keywords:
CampylobacterCohort studyGastroenteritisProton pump inhibitorSalmonella

More Related Videos

Construction of a Wireless-Enabled Endoscopically Implantable Sensor for pH Monitoring with Zero-Bias Schottky Diode-based Receiver
08:25

Construction of a Wireless-Enabled Endoscopically Implantable Sensor for pH Monitoring with Zero-Bias Schottky Diode-based Receiver

Published on: August 27, 2021

3.0K

Related Experiment Videos

Last Updated: Mar 24, 2026

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.5K
Construction of a Wireless-Enabled Endoscopically Implantable Sensor for pH Monitoring with Zero-Bias Schottky Diode-based Receiver
08:25

Construction of a Wireless-Enabled Endoscopically Implantable Sensor for pH Monitoring with Zero-Bias Schottky Diode-based Receiver

Published on: August 27, 2021

3.0K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Epidemiology

Background:

  • Proton pump inhibitors (PPIs) are widely used medications.
  • Previous studies have yielded conflicting results regarding the association between PPI use and bacterial gastroenteritis.
  • A robust investigation is needed to clarify this relationship.

Purpose of the Study:

  • To investigate the association between proton pump inhibitor (PPI) therapy and the incidence of bacterial gastroenteritis.
  • To quantify the risk of bacterial gastroenteritis associated with current PPI use.

Main Methods:

  • Prospective population-based cohort study (Rotterdam Study) with 14,926 participants (aged 45+).
  • Follow-up duration of up to 24 years.
  • Generalized estimating equations and nested case-control analyses were employed, focusing on participants with diagnostic stool samples.

Main Results:

  • Bacterial gastroenteritis was diagnosed in 125 participants.
  • Current PPI users were more likely to have bacterial gastroenteritis (adjusted OR 1.94).
  • Nested case-control analysis revealed a higher adjusted OR of 6.14 for current PPI users compared to the total cohort.

Conclusions:

  • Current proton pump inhibitor (PPI) therapy is associated with an elevated risk of developing bacterial gastroenteritis.
  • The study design minimized selection and information bias, suggesting the effect size is lower than previously reported.
  • Findings support a link between PPIs and increased susceptibility to bacterial gut infections.